Patents by Inventor Francois Hamy

Francois Hamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS
    Publication number: 20090226411
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7482352
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Substituted benzimidazole compounds and their use for the treatment of cancer
    Patent number: 7041668
    Abstract: The present invention discloses and claims benzimidazole compounds of formula (I): in which A is aryl or heteroaryl; R1 is selected from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH2; 1-imidazolyl or SO2Me; R2 is selected from optionally substituted —CO-alkyl, —CO-cycloalkyl, —CO-aralkyl, —CO-aryl, —CO-alkoxy, aryl or aralkyl, or —CO-amino, CO—NHR3 or CO—R3R4 wherein R3 and R4 are selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: May 9, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Francois Clerc, Francois Hamy, Isabelle Depaty, Odile Angouillant-Boniface, Stéphanie Deprets, Chantal Carrez, Manfred Roesner
  • Triazine derivatives and their application as antitelomerase agents
    Patent number: 6887873
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-François Riou, Gilles Doerflinger, Jean-Louis Mergny, François Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070571
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: November 19, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdekazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Substituted benzimidazole compounds and their use for the treatment of cancer
    Publication number: 20050014811
    Abstract: The present invention discloses and claims benzimidazole compounds of formula (I): in which A is aryl or heteroaryl; R1 is sleceted from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH2; 1-imidazolyl or SO2Me; R2 is selected from optionally substituted —CO-alkyl, —CO-cycloalkyl, —CO-aralkyl, —CO-aryl, —CO-alkoxy, aryl or aralkyl, or —O-amino, CO—NHR3 or CO—R3R4 wherein R3 and R4 are selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.
    Type: Application
    Filed: March 25, 2004
    Publication date: January 20, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Francois Clerc, Francois Hamy, Isabelle Depaty, Odile Angouillant-Boniface, Stephanie Deprets, Chantal Carrez, Manfred Roesner
  • Chemical derivatives and their application as antitelomerease agent
    Publication number: 20030087931
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: March 25, 2002
    Publication date: May 8, 2003
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield